Document is current
Any future updates will be listed below
-
Authors
Vaivade, Aina
Erngren, Ida https://orcid.org/0000-0001-7867-9525
Carlsson, Henrik
Freyhult, Eva https://orcid.org/0000-0003-0226-1047
Emami Khoonsari, Payam
Noui, Yassine https://orcid.org/0000-0002-0513-7546
Al-Grety, Asma
Åkerfeldt, Torbjörn
Spjuth, Ola https://orcid.org/0000-0002-8083-2864
Gallo, Valentina
Larsson, Anders Olof
Kockum, Ingrid https://orcid.org/0000-0002-0867-4726
Hedström, Anna Karin https://orcid.org/0000-0002-6612-4749
Alfredsson, Lars https://orcid.org/0000-0003-1688-6697
Olsson, Tomas
Burman, Joachim https://orcid.org/0000-0002-7045-1806
Kultima, Kim https://orcid.org/0000-0002-0680-1410
-
Funding
Funding for this research was provided by:
Vetenskapsrådet (2021–02189 and 2024-03161, 2021–02814)
Svenska Forskningsrådet Formas (2020–01267 and 2023-00905)
NEURO Sweden, Region Uppsala (ALF-grant and R&D funds), and Åke Wiberg
The Swedish Foundation for MS Research
Forte
Knut and Alice Wallenberg Foundation
Svenska Sällskapet för Medicinsk Forskning
The Marianne and Marcus Wallenberg Foundation, Region Uppsala
- License Information
-
More Information
Article History
Received: 29 April 2024
Accepted: 13 February 2025
First Online: 27 February 2025
Competing interests
: T.O. has received honoraria for lectures/advisory boards from Biogen, Novartis, Merck, and Sanofi and unrestricted MS research grants from the same companies, academic grants from The Swedish Research Council, the Swedish Brain Foundation, Knut and Alice Wallenberg Foundation, and Margaretha af Ugglas Foundation. L.A. has received honoraria for lectures Biogen, Merck, and Teva, as well as academic grants from The Swedish Research Council, the Swedish Brain Foundation, the Swedish Council for Health, Working Life and Health, Region Stockholm, and the insurance company AFA. IK has received honoraria for lectures from Merck as well as research collaborative support from Neurogene INC for an unrelated project. The remaining authors declare no competing interest.
